According to filings with the U.S. Securities and Exchange Commission, Cellanome is raising up to $149,999,997.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Omead Ostadan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cellanome
Cellanome is developing an automated platform to enable a richer understanding of individual cell behaviors, interactions, and functions across a range of stimuli and parameters, at massively parallel scale. Our focus is on enabling researchers to tackle new questions – broadening the range of cell types and functions that are accessible at scale. The platform enables iterative live cell phenotypic and functional assays, at scale, clearly linking each cell’s response to specific perturbations. This allows for a more granular view of the heterogeneity of cellular responses, highlighting individual cellular responses over bulk measurements, and facilitating combinatorial assays without needing to switch platforms or consume additional sample. The platform is compatible across a range of cell types, including large and challenging cell types, and enables observation of cell-to-cell interactions over time. It’s designed to integrate seamlessly into existing cell biology workflows, offering flexibility for modifying or creating new live cell assays.

To learn more about Cellanome, visit http://cellanome.com/

Contact:
Omead Ostadan, President and Chief Executive Officer
650-542-9878

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.